Analyzing the Future of Gastric Cancer Drugs Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the gastric cancer drugs market right now?
The market size for drugs used to treat gastric cancer has been expanding quickly in the past few years. Predictions show its growth from $4.43 billion in 2024 to $5.01 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. This historic growth is associated with the heightened spending on pharmaceutical research and development, boost in healthcare expenses, positive economic growth in developing markets, and the swift expansion of the senior population.
How fast Is the gastric cancer drugs market expected to grow, and what’s its future value?
The market for generative AI is anticipated to experience tremendous expansion in the upcoming years, reaching $113.42 billion by 2029, with a compound annual growth rate (CAGR) of 34.7%. The surge during this projected period can be accredited to progress in AI hardware technologies, integration across various industries, considerations around ethical AI, independent systems, and the implementation of edge computing. Key trends in this period are expected to be the increase in AI-created content, customization and personalization, applications across different domains, addressing bias in AI ethically, and cooperation between humans and AI.
Get your gastric cancer drugs market report here!
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
What are the leading drivers of growth in the gastric cancer drugs market?
The rise in the number of people with obesity and the growing smoking population has led to a surge in individuals battling gastric cancer. Unhealthy dietary habits and tobacco use escalate the risk of developing this type of cancer. For example, the Government Digital Service, a governmental entity in the UK, reported in May 2023 that the obesity rate among individuals 18 and older in England, had jumped to 25.9% in 2022–2022 from 25.2%. This escalating trend in the incidence of gastric cancer is likely to stimulate the growth of the gastric cancer drugs market.
What are the key segments defining the gastric cancer drugs market?
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp
Who are the key players steering the development of the gastric cancer drugs market?
Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health
What emerging trends are influencing the growth of the gastric cancer drugs market?
Leading firms in the gastric cancer drugs market, like Merck & Co., Inc., are developing innovative offerings such as anti-PD-1 therapies to bolster treatment efficiency and enhance patient recovery. Anti-PD-1 therapy, a form of immunotherapy, targets the programmed cell death protein 1 (PD-1) receptor found on immune cells. As an example, in November 2023, the US-based pharmaceutical company Merck & Co., Inc. obtained approval from the Food and Drug Administration (FDA), responsible for public health protection in the US, for the use of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy used in gastric cancer treatment. KEYTRUDA is designed for first-line treatment of patients suffering from locally advanced cancer that is unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is specifically imported for use with trastuzumab and chemotherapy that contains fluoropyrimidine and platinum. The approval for this indication was fast-tracked based on the tumor response rate along with response duration.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603
Which regions are most influential in expanding the gastric cancer drugs market?
North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Diuretics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report
Genito-Urinary Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report
Musculoskeletal Disorders Drugs Global Market Report 2022
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
